Lv75
3680 积分 2022-12-19 加入
Iberdomide for minimal residual disease-negative myeloma—from underdog to the spotlight
16小时前
已完结
In Vivo CAR T-Cell Therapy Spurs 100% ORR in Phase I
7天前
已完结
Frailty and quality of life in a real‐world multiple myeloma population
10天前
已完结
Cardiovascular Toxicities of Contemporary Cancer Immunotherapies: A Narrative Review of Immune Checkpoint Inhibitors, Bispecific T-Cell Engagers, and CAR-T Cell Therapies
10天前
已完结
A Myeloma Masquerade: CCND3 ‐Rearranged Plasma Cell Myeloma Mimicking Lymphoplasmacytic Lymphoma
12天前
已完结
[Diagnosis and treatment of multiple myeloma in China over the past two decades: current status and challenges]
15天前
已完结
[Treatment of relapsed/refractory multiple myeloma: new recommendations based on new evidence]
15天前
已完结
Lymphoma, Leukemia & Myeloma Congress 2026 Abstracts
16天前
已完结
Renal rescue in myeloma: How deep does the hematologic response need to be?
18天前
已完结
Bispecific antibody-associated desquamative palmoplantar dermatitis: a distinct palmoplantar toxicity beyond HFS and HFSR
18天前
已完结
皖公网安备34019202002308
